These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 11549532

  • 21. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
    Brusasco V, Canonica GW, Dal Negro R, Scano G, Paggiaro P, Fabbri LM, Barisione G, D'Amato G, Varoli G, Baroffio M, Milanese M, Mereu C, Crimi E.
    J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):235-43. PubMed ID: 21689019
    [Abstract] [Full Text] [Related]

  • 22. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
    Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, Bateman E.
    Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
    [Abstract] [Full Text] [Related]

  • 23. [Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease].
    Zheng JP, Kang J, Cai BQ, Zhou X, Cao ZL, Bai CX, Zhong NS.
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):363-7. PubMed ID: 17045014
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
    Zhong N, Zheng J, Wen F, Yang L, Chen P, Xiu Q, Yao W, Sun T, Zhao Z, Shen H, Shi Y, Lin J, Li Q.
    Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
    [Abstract] [Full Text] [Related]

  • 25. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 26. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease.
    Campbell SC, Criner GJ, Levine BE, Simon SJ, Smith JS, Orevillo CJ, Ziehmer BA.
    Pulm Pharmacol Ther; 2007 Aug; 20(5):571-9. PubMed ID: 16911869
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
    Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R.
    Am J Respir Crit Care Med; 2009 Oct 15; 180(8):741-50. PubMed ID: 19644045
    [Abstract] [Full Text] [Related]

  • 28. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y, Samoro R, Fassakhov R, Taniguchi H, Ekelund J, Carlsson LG, Ichinose M.
    Respirology; 2013 Jul 15; 18(5):866-73. PubMed ID: 23551359
    [Abstract] [Full Text] [Related]

  • 29. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
    Tashkin DP, Hanania NA, McGinty J, Denis-Mize K, Chaudry I.
    Adv Ther; 2009 Nov 15; 26(11):1024-34. PubMed ID: 19953349
    [Abstract] [Full Text] [Related]

  • 30. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.
    Whale CI, Sovani MP, Mortimer KJ, Harrison TW, Tattersfield AE.
    Br J Clin Pharmacol; 2008 Jun 15; 65(6):841-7. PubMed ID: 18394012
    [Abstract] [Full Text] [Related]

  • 31. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb 15; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 32. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug 15; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

  • 33. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R, Creemers JP, Van Noord J, Sips A, Della Cioppa G, Thomson M, Andriano K, Kottakis J, Fashola T.
    Respiration; 2004 Aug 15; 71(2):126-33. PubMed ID: 15031566
    [Abstract] [Full Text] [Related]

  • 34. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K, Formoterol Study Group.
    Clin Ther; 2007 Oct 15; 29(10):2167-78. PubMed ID: 18042473
    [Abstract] [Full Text] [Related]

  • 35. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
    Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R.
    Respir Med; 2007 Sep 15; 101(9):1931-41. PubMed ID: 17544264
    [Abstract] [Full Text] [Related]

  • 36. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
    Bouros D, Kottakis J, Le Gros V, Overend T, Della Cioppa G, Siafakas N.
    Curr Med Res Opin; 2004 May 15; 20(5):581-6. PubMed ID: 15140323
    [Abstract] [Full Text] [Related]

  • 37. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.
    Celli BR, Tashkin DP, Rennard SI, McElhattan J, Martin UJ.
    Respir Med; 2011 Aug 15; 105(8):1176-88. PubMed ID: 21531124
    [Abstract] [Full Text] [Related]

  • 38. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD.
    Meyer T, Reitmeir P, Brand P, Herpich C, Sommerer K, Schulze A, Scheuch G, Newman S.
    Respir Med; 2011 Jun 15; 105(6):900-6. PubMed ID: 21397483
    [Abstract] [Full Text] [Related]

  • 39. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
    Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehart M, Denis-Mize K.
    Ther Adv Respir Dis; 2008 Aug 15; 2(4):199-208. PubMed ID: 19124372
    [Abstract] [Full Text] [Related]

  • 40. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
    Cazzola M, Noschese P, Salzillo A, De Giglio C, D'Amato G, Matera MG.
    Respir Med; 2005 May 15; 99(5):524-8. PubMed ID: 15823447
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.